03:59 PM EST - Allon Therapeutics Inc. : said its neuroprotective drug candidate, davunetide, has been granted Fast Track status from the U.S. Food and Drug Administration or FDA for the treatment of Progressive Supranuclear Palsy or PSP, a rapidly-progressing and fatal degenerative brain disease. Fast Track status is designed to facilitate development and expedite review of a drug candidate that treats a serious or life-threatening condition and addresses an unmet medical need, the company stated. Allon Therapeutics Inc.
shares T.NPC are trading up $0.07 at $0.63.
